Sanofi entered into an exclusive global license agreement with Sino Biopharmaceutical's subsidiary, Chia Tai Tianqing Pharmaceutical Group, for rovadicitinib.[1] This oral JAK/ROCK inhibitor is indicated for the treatment of blood cancers and has recently received approval in China.[1] The value of the agreement reaches up to 1.53 billion dollars.[1] It includes an upfront payment of $135 million and potential milestone payments of up to $1.40 billion for development, regulatory and sales.[1] The agreement gives Sanofi the rights to develop, manufacture and commercialize the drug worldwide.[1] Rovadicitinib was approved by Chinese regulators last month.[1] The contract was announced on March 4.[1]